GlycoEra
Newton, US · 9 known investors
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs. The company operates in the biotech and drug development space.
Founders & leadership
GV
Ganesh V. KaundinyainPresident & CEO
Investors · 9
5AM VenturesBoston · $100K – $4M
Catalio Capital Management, LPNew York
LifeArc VenturesLondon
Roche Venture FundBasel · $648K – $3.2M
Sixty Degree CapitalNorth York
Sofinnova PartnersParis · $540K – $27M
Agent Capitalreported · 2 sourcesWaltham
Novo HoldingsreportedCopenhagen · $1.1M – $54M
Also in the syndicate · 1
Novo
Funding
SEC filings, press & company announcements$130M disclosed across 1 of 3 rounds · 2025
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 6
by search overlap
AbCellera17 shared keywordsAbCellera develops antibody-based medicines using a technology platform that integrates biology, computation, and engineering, working with pharmaceutical partners on antibody drug programs including bispecifics and antibody drug conjugates. The company operates in the biotech and drug discovery sector, focusing on first-in-class and best-in-class antibody therapeutics for complex targets such as transmembrane proteins.
Nuclera15 shared keywordsNuclera develops eProtein Discovery, a benchtop protein screening system that uses cell-free protein synthesis and digital microfluidics to design, screen, characterize, and express proteins in-house. It serves research scientists working on antibody discovery and protein studies, including soluble, membrane, and antibody fragment targets.
Deciphera9 shared keywordsDeciphera is a pharmaceutical company focused on developing treatments for people living with cancer. Its work centers on oncology drug development and support for patient communities.
Chimera Bioengineering9 shared keywordsChimera develops engineered cell therapies for cancer that produce therapeutic proteins only upon encountering tumor cells, using natural biological control mechanisms to improve safety and efficacy. The company focuses on treating solid tumors and other currently incurable cancers through localized, controlled immune cell activation.
Galera Therapeutics9 shared keywordsGalera Therapeutics is a biotechnology company developing antibody-based and other therapeutics. This page profiles Dr. Nancy Chang, a member of the company's Board of Directors.
Kymera Therapeutics9 shared keywordsKymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.
Companies competing with GlycoEra for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does GlycoEra do?
- GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs. The company operates in the biotech and drug development space.
- Who are GlycoEra's investors?
- GlycoEra's investors include 5AM Ventures, Catalio Capital Management, LP, LifeArc Ventures, Roche Venture Fund, Sixty Degree Capital, Sofinnova Partners, Agent Capital, Novo Holdings.
- How much funding has GlycoEra raised?
- GlycoEra has disclosed $130M raised across 1 of its 3 known rounds.
- Where is GlycoEra headquartered?
- GlycoEra is headquartered in Newton, US.